Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179660 | 0.86 | CTSL (0.51) | HDAC1HDAC8HDAC6ALDH1A1GAA | |
| SCHEMBL8327055 | 0.83 | CASP3 (0.49) | ALDH1A1GAAFPR1FPR2CTSL | |
| SCHEMBL8326106 | 0.80 | CASP3 (0.47) | ALDH1A1GAAFPR1FPR2CTSL | |
| SCHEMBL253913 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL14601914 | 0.79 | CTSK (0.54) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL4683464 | 0.79 | TSHR (0.53) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL4679772 | 0.79 | TSHR (0.53) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL13043801 | 0.79 | CTSK (0.54) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL4679774 | 0.79 | TSHR (0.53) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL4480037 | 0.79 | CASP3 (0.45) | ALDH1A1GAAFPR1FPR2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060229317-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2006-10-12 | — | — | US | disclosed |
| US-7115610-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050197346-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2005061470-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229317-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CCR1 3344/4885HDAC1 407/4885HDAC8 836/4885 |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CCR1 3344/4885HDAC1 407/4885HDAC8 836/4885 |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CCR1 3344/4885HDAC1 407/4885HDAC8 836/4885 |
| US-20050197346-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CCR1 3344/4885HDAC1 407/4885HDAC8 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.